Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score

Iria Veiga Teijeiro, Indhira Guzmán Peralta, Luis Pérez De Llano, Irene Martín Robles, Nagore Blanco Cid, David Dacal Rivas, Ignacio Davila, Eva Martínez-Moragón, Javier Domínguez Ortega, Carlos Almonacid, Carlos Colás, Juan Luis García-Rivero, Loreto Carmona, María Jesús García De Yébenes, Borja García-Cosío
European Respiratory Journal 2021 58: PA1098; DOI: 10.1183/13993003.congress-2021.PA1098
Iria Veiga Teijeiro
1Lucus Augusti University Hospital, Lugo, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: iriaveigat@hotmail.com
Indhira Guzmán Peralta
1Lucus Augusti University Hospital, Lugo, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Pérez De Llano
1Lucus Augusti University Hospital, Lugo, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene Martín Robles
1Lucus Augusti University Hospital, Lugo, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nagore Blanco Cid
1Lucus Augusti University Hospital, Lugo, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Dacal Rivas
1Lucus Augusti University Hospital, Lugo, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ignacio Davila
2Salamanca University Hospital, Salamanca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Martínez-Moragón
3Doctor Peset University Hospital, Valencia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Domínguez Ortega
4La Paz University Hospital, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Almonacid
5Ramón y Cajal University Hospital, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Colás
6Lozano Blesa University Clinical Hospital, Zaragoza, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Luis García-Rivero
7Laredo Hospital, Laredo, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loreto Carmona
8Santiago de Compostela University Hospital, Santiago de Compostela, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Jesús García De Yébenes
9InMusc Institute, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Borja García-Cosío
10Son Espases University Hospital, Palma de Mallorca, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: There is a lack of tools to holistically quantify the response to monoclonal antibodies (mAbs) in severe uncontrolled asthma (SUA) patients. The aim of this study was to develop a valid score to assist specialists in this clinical context.

Methods: The score was developed in 4 subsequent phases: (1) elaboration of the theoretical model of the construct intended to be measured (response to mAbs); (2) definition and selection of items and measurement instruments by Delphi survey; (3) weight assignment of the selected items by multicriteria decision analysis (MCDA) using the Potentially All Pairwise RanKings of all possible Alternatives (PAPRIKA) methodology via the 1000Minds software; and (4) face validity assessment of the obtained score.

Results: Four core items, with different levels of response for each of them, were selected: “severe exacerbations”, “oral corticosteroid use”, “symptoms” (evaluated by Asthma Control Test: ACT) and “bronchial obstruction” (assessed by FEV1% theoretical). “Severe exacerbations” and “oral corticosteroid maintenance dose” were weighted most heavily (38% each), followed by “symptoms” (13%) and “FEV1” (11%). Higher scores in the weighted system indicate better response and the range of responses runs from 0 (worsening) to 100 (best possible response). Face validity was high (intraclass correlation coefficient: 0.86).

Conclusions: The FEOS score (FEV1, Exacerbations, Oral corticosteroids, Symptoms) allows clinicians to quantify response in SUA patients who are being treated with mAbs.

  • Severe asthma
  • Personalised medicine
  • Monitoring

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1098.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score
Iria Veiga Teijeiro, Indhira Guzmán Peralta, Luis Pérez De Llano, Irene Martín Robles, Nagore Blanco Cid, David Dacal Rivas, Ignacio Davila, Eva Martínez-Moragón, Javier Domínguez Ortega, Carlos Almonacid, Carlos Colás, Juan Luis García-Rivero, Loreto Carmona, María Jesús García De Yébenes, Borja García-Cosío
European Respiratory Journal Sep 2021, 58 (suppl 65) PA1098; DOI: 10.1183/13993003.congress-2021.PA1098

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score
Iria Veiga Teijeiro, Indhira Guzmán Peralta, Luis Pérez De Llano, Irene Martín Robles, Nagore Blanco Cid, David Dacal Rivas, Ignacio Davila, Eva Martínez-Moragón, Javier Domínguez Ortega, Carlos Almonacid, Carlos Colás, Juan Luis García-Rivero, Loreto Carmona, María Jesús García De Yébenes, Borja García-Cosío
European Respiratory Journal Sep 2021, 58 (suppl 65) PA1098; DOI: 10.1183/13993003.congress-2021.PA1098
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Airway resistance and characterization of airway obstruction
  • Late Breaking Abstract - The effect of comorbidity on the course and outcomes of COPD in observation in the primary health care, including on the background of the COVID-19 pandemic: a comparative analysis
  • Methotrexate treatment in recent onset RA does not change the NO dynamics of the lung
Show more Monitoring airway disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society